Discordant Trial Results Among Issues FDA Bringing To Advisory Panel Review Of Novartis' Afinitor

The change in endpoints for the two pivotal studies in neuroendocrine tumors and the fact that they don't support each other will fuel the Oncologic Drugs Advisory Committee discussion of the new indication for everolimus.